Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration

Clinical Cancer Research

Volumn 6, Issue 11, 2000, Pages 4186-4191

  Stewart, Alistair ^a   Steiner, Jan ^a   Mellows, Graham ^a   Laguda, Bim ^a   Norris, David ^a   Bevan, Paul ^a  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRANILIC ACID DERIVATIVE; CD56 ANTIGEN; CYTOTOXIC AGENT; GLYCOPROTEIN P; RHODAMINE 123; TARIQUIDAR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE; MULTIDRUG RESISTANCE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIGENS, CD56; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE, NEOPLASM; HUMANS; INJECTIONS, INTRAVENOUS; LYMPHOCYTES; MIDDLE AGED; P-GLYCOPROTEIN; QUINOLINES;

EID: 0033740397     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. P-glycoprotein: A mediator of multidrug resistance in tumour cells
2. Biochemistry of multidrug resistance mediated by the multidrug transporter
3. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations
4. Clinical trials of agents that reverse multidrug resistance
5. Reversal of Pglycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979
6. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumour cells with SDZ PSC 833
7. SDZ PSC 833/paclitaxel in paclitaxel refractory ovarian carcinoma: A Phase II trial with renewed responses
8. XR9576, a potent modulator of P-glycoprotein-mediated multidrug resistance
9. In vitro and in vivo evaluation of XR9576, a novel potent modulator of P-glycoprotein (P-gp) mediated multidrug resistance (MDR)
10. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein
11. Flow cytometric analysis of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918
12. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridone carboxamide derivative
13. An intravenous Phase I study with the novel P-glycoprotein-dependent multidrug resistance modulator, XR9576, demonstrates surrogate marker activity in situ